Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review

Meity Ardiana; Asiyah Nurul Fadila; Zakirah Zuhra; Nabilla Merdika Kusuma; Made Edgard Surya Erlangga Rurus; Delvac Oceandy

doi:10.1016/j.ncrna.2023.06.002

Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review

Meity Ardiana
, Asiyah Nurul Fadila
, Zakirah Zuhra
, Nabilla Merdika Kusuma
, Made Edgard Surya Erlangga Rurus
, Delvac Oceandy

Division of Cardiovascular Sciences (L5)

Dr. Soetomo General Academic Hospital
University of Indonesia
Hang Tuah University

Research output: Contribution to journal › Review article › peer-review

Abstract

At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.

Original language	English
Pages (from-to)	487-506
Number of pages	20
Journal	Non-coding RNA research
Volume	8
Issue number	4
Early online date	1 Jul 2023
DOIs	https://doi.org/10.1016/j.ncrna.2023.06.002
Publication status	Published - 1 Dec 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cardiogenetics
Cardiovascular diseases
Cardiovascular risk factors
Non-coding RNA
RNA therapeutics

Access to Document

10.1016/j.ncrna.2023.06.002Licence: CC BY

Cite this

@article{4ee50918598f49bbb0b8dcc017e23e45,

title = "Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review",

abstract = "At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.",

keywords = "Cardiogenetics, Cardiovascular diseases, Cardiovascular risk factors, Non-coding RNA, RNA therapeutics",

author = "Meity Ardiana and Fadila, \{Asiyah Nurul\} and Zakirah Zuhra and Kusuma, \{Nabilla Merdika\} and \{Surya Erlangga Rurus\}, \{Made Edgard\} and Delvac Oceandy",

note = "{\textcopyright} 2023 The Authors.",

year = "2023",

month = dec,

day = "1",

doi = "10.1016/j.ncrna.2023.06.002",

language = "English",

volume = "8",

pages = "487--506",

journal = "Non-coding RNA research",

issn = "2468-0540",

publisher = "Ke Ai Publishing",

number = "4",

}

TY - JOUR

T1 - Non-coding RNA therapeutics in cardiovascular diseases and risk factors

T2 - Systematic review

AU - Ardiana, Meity

AU - Fadila, Asiyah Nurul

AU - Zuhra, Zakirah

AU - Kusuma, Nabilla Merdika

AU - Surya Erlangga Rurus, Made Edgard

AU - Oceandy, Delvac

PY - 2023/12/1

Y1 - 2023/12/1

N2 - At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.

AB - At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.

KW - Cardiogenetics

KW - Cardiovascular diseases

KW - Cardiovascular risk factors

KW - Non-coding RNA

KW - RNA therapeutics

UR - https://www.scopus.com/pages/publications/85164279999

U2 - 10.1016/j.ncrna.2023.06.002

DO - 10.1016/j.ncrna.2023.06.002

M3 - Review article

C2 - 37483458

SN - 2468-0540

VL - 8

SP - 487

EP - 506

JO - Non-coding RNA research

JF - Non-coding RNA research

IS - 4

ER -

Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this